|
|
Article: Sepracor Announces Presentation of LUNESTA(TM) Data at American Psychiatric Association Annual Meeting.
- Article from:
- Business Wire
- Article date:
- May 25, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced that data from its Phase IIIB/IV studies of LUNESTA(TM) brand eszopiclone for the treatment of insomnia were presented at the annual meeting of the American Psychiatric Association in Toronto.
--The Effect of Eszopiclone 3 mg Compared with Placebo in Patients with Rheumatoid Arthritis (RA) and Co-Existing Insomnia
In this Phase IIIB/IV, 153-patient, four-week, randomized, double-blind, placebo-controlled pilot study, nightly use of LUNESTA 3 mg resulted in statistically significant improvement from baseline compared with placebo in patient-reported measures of sleep latency (onset of ...